Publication & Citation Trends
Publications
131 total
HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd
Cited by 3
Semantic Scholar
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
Cited by 28
Semantic Scholar
111MO Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase III PANTHER trial OA
Cited by 0
Semantic Scholar
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
Cited by 10
Semantic Scholar
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial
Cited by 5
Semantic Scholar
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Cited by 231
OpenAlex
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Cited by 554
OpenAlex
Research Topics
Breast Cancer Treatment Studies
(35)
HER2/EGFR in Cancer Research
(25)
Cancer Treatment and Pharmacology
(24)
Advanced Breast Cancer Therapies
(13)
Diverse Scientific and Economic Studies
(13)
Affiliations
Roche (Switzerland)
University of Vienna
Amgen (United States)
Barwon Health
University of California, Los Angeles